Targeting NKG2D Ligands in Glioblastoma with a Bispecific T-Cell Engager Is Augmented with Conventional Therapy and Enhances Oncolytic Virotherapy of Glioma Stem-Like Cells

Researchers designed a bispecific T cell engager capable of cross-linking CD3 on T cells with NKG2DL-expressing GBM cells. They then engineered the G207 virus to express the NKG2D BiTE and secrete it from infected cells.
[Journal For Immunotherapy Of Cancer]
Full Article